# Berberine Insulin Resistance Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/berberine-insulin-resistance-meta-analysis-evidence-review
Category: evidence-review
Summary: Berberine Insulin Resistance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass 
Last reviewed: 2026-06-08
Reviewed by: Migaku Evidence Review
# Berberine Insulin Resistance Meta-analysis: What the Evidence Says

## Quick Answer

Berberine Insulin Resistance Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 systematic review, 1 narrative review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Probiotics, synbiotics and berberine in Type 2 diabetes mellitus: A systematic review, meta-analysis, and molecular dynamics simulation study | systematic review | 1 | 2026-05-29 | 10.1371/journal.pone.0348907 |
| Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications | narrative review | 3 | 2026-03-12 | 10.3390/biomedicines14030646 |

## What The Sources Report

- The disease is associated with substantial morbidity and mortality, primarily due to its long-term complications such as cardiovascular disease, nephropathy, neuropathy, and retinopathy. [Shadin Md. (2026); evidence level 1]
- Beyond health consequences, T2DM imposes a considerable economic burden on healthcare systems and societies, contributing to reduced productivity and increased healthcare expenditures. [Shadin Md. (2026); evidence level 1]
- The concept of metabolic syndrome was first introduced in 1988 as "Syndrome X" to describe the frequent clustering of insulin resistance with metabolic abnormalities that increase the risk of type 2 diabetes mellitus and cardiovascular disease. [Starvaggi Josè (2026); evidence level 3]
- This definition identifies metabolic syndrome based on the presence of at least three of the following components: increased waist circumference (population specific), hypertriglyceridemia and/or reduced HDL cholesterol, elevated blood pressure, and impaired fasting glucose. [Starvaggi Josè (2026); evidence level 3]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For berberine insulin resistance meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Shadin Md. (2026). Probiotics, synbiotics and berberine in Type 2 diabetes mellitus: A systematic review, meta-analysis, and molecular dynamics simulation study. DOI: 10.1371/journal.pone.0348907. PMCID: PMC13221027. PMID: 42213651. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13221027/
- Starvaggi Josè (2026). Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications. DOI: 10.3390/biomedicines14030646. PMCID: PMC13024294. PMID: 41898291. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13024294/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.